Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus
- 21 November 2003
- journal article
- Published by Elsevier in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 339 (1-2) , 85-90
- https://doi.org/10.1016/j.cccn.2003.09.007
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic PatientsCirculation, 2003
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated Type 2 diabetesDiabetic Medicine, 2002
- CD154-Dependent Priming of Diabetogenic CD4+ T Cells Dissociated from Activation of Antigen-Presenting CellsImmunity, 2002
- Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetesProceedings of the National Academy of Sciences, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory CellsImmunity, 2002
- The CD40/CD154 receptor/ligand dyadRID="†"ID="†" ReviewCellular and Molecular Life Sciences, 2001
- Evaluation of Platelet Function by Flow CytometryMethods, 2000
- Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotypeProceedings of the National Academy of Sciences, 2000